Srinivas Rao - 13 Aug 2025 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Reporting relationship: Co-Founder and Chief Executive Officer
Issuer ticker: ATAI
Reported as of: 13 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Aug 2025, 17:30:39 UTC
Prior SEC filing: 24 Mar 2025
Next SEC filing: 03 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Ryan Barrett, Attorney-in-fact

Key filing fact

Srinivas Rao filed Form 4 for ATAI Life Sciences N.V. (ATAI) on 15 Aug 2025.

Key facts

This page summarizes Srinivas Rao's Form 4 filing for ATAI Life Sciences N.V. (ATAI).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 15 Aug 2025, 17:30.

Change

Previous filing in this sequence was filed on 24 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001860902 Primary reporting owner

Rao Srinivas

Relationship: Co-Founder and Chief Executive Officer
Address: C/O ATAI LIFE SCIENCES N.V., PROF. J.H. BAVINCKLAAN 7, AMSTERDAM, NETHERLANDS
Signature: /s/ Ryan Barrett, Attorney-in-fact
Signature date: 15 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATAI transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +650,794
Change %
Price: $0.000000
Shares after: 650,794
Date: 13 Aug 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 650,794
Exercise price: $5.68
Footnotes: F1

ATAI transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +217,777
Change %
Price: $0.000000
Shares after: 217,777
Date: 13 Aug 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 217,777
Exercise price: $2.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

No new stock options have been awarded. The transactions reported herein reflect vesting of performance-based stock options ("Performance Options") previously awarded to the Reporting Person on January 20, 2021, vesting subject to performance conditions that were subsequently satisfied, as certified and approved by the board of directors of atai Life Sciences NV as of August 13, 2025. The portion of the Performance Options is fully vested and currently exercisable with respect to the shares reported herein.

SEC remarks

Co-Founder and Chief Executive Officer